{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:15:13Z","timestamp":1788642913936,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.leukres.2010.05.003","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T08:40:23Z","timestamp":1275554423000},"page":"1330-1335","source":"Crossref","is-referenced-by-count":14,"title":["The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma\u2014A report by the Polish Myeloma Study Group"],"prefix":"10.1016","volume":"34","author":[{"given":"Anna","family":"Dmoszynska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Walter-Croneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Grzasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Manko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieslaw Wiktor","family":"Jedrzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Charlinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Usnarska-Zubkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Wolska-Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Piszcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Kloczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.05.003_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.05.003_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.003_bib3","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients","volume":"86","author":"Hus","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.05.003_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2002-05-1527","article-title":"Efficacy of a low dose of thalidomide in advanced multiple myeloma","volume":"100","author":"Leleu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.003_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.leukres.2010.05.003_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.leukres.2010.05.003_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.003_bib8","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.003_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.12-1-99","article-title":"Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21","volume":"12","author":"Suvannasankha","year":"2007","journal-title":"Oncologist"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2010.05.003_bib10","first-page":"177","article-title":"Clinical efficacy of thalidomide containing regimens as a first line therapy in patients with multiple myeloma","volume":"92","author":"Kim","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.05.003_bib11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428190600821955","volume":"47","author":"Wu","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.003_bib12","first-page":"300","article-title":"Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells","volume":"49","author":"Fiserova","year":"2002","journal-title":"Neoplasma"},{"key":"10.1016\/j.leukres.2010.05.003_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"4 Suppl. 4","key":"10.1016\/j.leukres.2010.05.003_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2003.09.006","article-title":"Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma","volume":"40","author":"Alexanian","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.05.003_bib15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/10428190601186168","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments","volume":"48","author":"Roussou","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.05.003_bib16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.003_bib17","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/sj.bjc.6602225","article-title":"An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma","volume":"91","author":"Hus","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2010.05.003_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.05.003_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.05.003_bib20","doi-asserted-by":"crossref","first-page":"1051A","DOI":"10.1182\/blood.V110.11.3593.3593","article-title":"Thalidomide combination improve response rates; results from MRC IX study","volume":"110","author":"Morgan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.05.003_bib21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.leukres.2010.05.003_bib22","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1538-7836.2006.02059.x","article-title":"Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Italian Multiple Myeloma Network, Gimema","volume":"4","author":"Palumbo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2010.05.003_bib23","first-page":"169","article-title":"CTD treatment of myeloma - a single institution's experience","volume":"92","author":"Mangles","year":"2007","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261000247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261000247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T09:56:37Z","timestamp":1591350997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261000247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S014521261000247X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.05.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}